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RNAi is evolving into a powerful tool for manipulating gene expression in mammalian cells with potential utility for investigat-
ing gene function, for high-throughput, function-based genetic screens and potentially for development as a therapeutic tool.
Introduction
Since the 1970s, the war on cancer has been based on the
notion that studying the disease will lead to the discovery of vul-
nerabilities that can be exploited in the clinic.While many under-
lying genetic determinants of cancer have been identified, this
knowledge has failed to translate into new therapeutic strate-
gies, with a handful of notable exceptions. One hypothesis is
that this failure has largely been due to the genetically
intractable nature of cultured mammalian cells. The recent
emergence of dsRNA-induced gene silencing, or RNA interfer-
ence (RNAi), in mammalian systems is likely to reinvigorate the
field of somatic cell genetics, and in the process revolutionize
the study of human disease. During the past year, a point has
been reached at which any gene in the human genome can
conceivably be targeted using small, dsRNA gene-silencing
triggers—small interfering RNAs (siRNAs) or expressed short
hairpin RNAs (shRNAs). The application of siRNAs and
shRNAs for single gene analysis is rapidly becoming standard
methodology, and genome-wide reverse genetic screens are
certainly on the horizon.The future of RNAi may lie in the devel-
opment of highly specific, nucleic acid-based therapies for can-
cer and other diseases.
RNAi in invertebrate systems
RNAi first emerged as a biological oddity in C. elegans (Fire et
al., 1998) and plants (Jorgensen et al., 1996), but was quickly
harnessed as a powerful genetic tool in these systems.
However, it has become clear that dsRNA-induced silencing
phenomena are present in evolutionarily diverse organisms,
including plants, fungi, and metazoans (reviewed in Bernstein et
al., 2001b; Hammond et al., 2001). A combination of genetic
and biochemical studies suggest that many of these phenome-
na share a common mechanism (Figure 1). The prevailing
model begins with the conversion of the dsRNA silencing “trig-
ger” into small RNAs (siRNAs) by an RNase III family nuclease,
Dicer (Bernstein et al., 2001a). These small RNAs (?22–25 nt
in size) become incorporated into a multicomponent nuclease
complex, which uses the sequence of the siRNAs as a guide to
identify and destroy homologous mRNAs (Tuschl et al., 1999;
Hammond et al., 2000; Zamore et al., 2000; Nykanen et al.,
2001).
So far, the only universally conserved players in RNAi are
Dicer and Argonaute (Ago) gene family members. Dicer con-
tains a tandem repeat of RNaseIII catalytic domains, a carboxyl-
terminal dsRNA binding domain, an amino-terminal
DExH/DEAH RNA helicase domain, and a PAZ domain
(Bernstein et al., 2001a; Nicholson and Nicholson, 2002). Ago
proteins, which are components of the RNA-induced silencing
complex (RISC), contain a PAZ domain and a carboxyl-terminal
PIWI domain.
The RNAi pathway may have evolved early in eukaryotes as
a cell-based immunity against viral and genetic parasites.
Double-stranded RNA viruses or mobile genetic elements with
the potential to form dsRNA structures are virtually ubiquitous
and may be subject to RNAi-dependent gene silencing in C. ele-
gans, plants, Drosophila, yeast, and mammals (reviewed in
Hannon, 2002). However, the RNAi pathway is also used for the
regulation of endogenous gene targets during metazoan and
plant development (reviewed in Hannon, 2002).
Endogenously expressed small hairpin RNAs regulate gene
expression through the RNAi pathway during C. elegans devel-
opment (Reinhart et al., 2000; Grishok et al., 2001; Hutvagner
et al., 2001; Ketting et al., 2001; Knight and Bass, 2001;
Figure 1. A model for RNA interference in mammalian cells
Small double-stranded RNA triggers of RNAi (shRNAs and siRNAs) are
shown, expressed from RNA polymerase III promoters. Short hairpin RNAs
(shRNAs), containing 1929 nt dsRNA stems, are processed by Dicer and
incorporated into the RNA induced silencing complex (RISC), resulting in
the targeting and degradation of cognate mRNAs. Small interfering RNAs
(siRNAs), containing 19 nt or 21 nt of dsRNA, presumably bypass the require-
ment for Dicer and are directly incorporated into RISC.
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reviewed in Hannon, 2002). These small hairpin RNAs (?70 nt)
are processed into a 21–22 nt mature form by Dicer and then
used to seek out mRNA targets of similar sequence (generally
via imperfect base-pairing interactions). For the two prototypes
of this family, C. elegans lin-4 and let-7, silencing occurs at the
level of protein synthesis (reviewed in Bernstein et al., 2001b).
The first small hairpin RNAs were dubbed small temporal RNAs
(stRNAs), owing to their role in developmental timing (Lee et al.,
1993; Wightman et al., 1993; Ha et al., 1996; Slack et al., 2000).
More recently, dozens of orphan hairpins have been identified in
C. elegans, Drosophila, mouse, and humans, which are collec-
tively referred to as microRNAs (miRNAs) (Pasquinelli et al.,
2000; Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and
Ambros, 2001; Mourelatos et al., 2002).
RNAi and related pathways underlie many homology-
dependent silencing phenomena, including cosuppression,
virus-induced gene silencing, transgene-induced silencing, and
quelling (reviewed in Bernstein et al., 2001b). These silencing
phenomena variably involve either Post-Transcriptional Gene
Silencing (PTGS), Transcriptional Gene Silencing (TGS), or
both. RNAi in C. elegans appears to solely involve PTGS, while
in plants the same dsRNA trigger can target both mRNA and
chromatin.
RNAi in mammals
Given the strong conservation of RNAi-related genes in verte-
brates, including Dicer and Argonaute family members, the
expectation was that RNAi would operate in mammalian cells in
some capacity. The first glimpse of RNAi in mammals came
from injections of long dsRNAs (?500 nt, similar to those used
to trigger RNAi in invertebrate systems) into mouse embryos,
which resulted in sequence-specific gene silencing (Svoboda et
al., 2000; Wianny and Zernicka-Goetz, 2000). Several groups,
including our own, extended these findings to embryonal cell
lines (Billy et al., 2001; Yang et al., 2001; Paddison et al.,
2002a). Biochemical and genetic evidence from these studies
suggested that RNAi operates in at least a subset of mam-
malian cell types, in a Dicer-dependent manner via posttran-
scriptional mechanisms (Billy et al., 2001; Paddison et al.,
2002a).
In somatic cells, however, the use of conventional dsRNA
triggers (?500 nt dsRNAs) is limited by antiviral/interferon
responses, including the PKR and RNaseL pathways (Baglioni
and Nilsen, 1983; Clarke and Mathews, 1995; Gil and Esteban,
2000; reviewed in Williams, 1997), which trigger generalized
translational repression and apoptosis in response to dsRNA of
>30 bp in length. Even where PKR activity is removed from
somatic cells, by either viral inhibitors or targeted disruption,
long dsRNA still triggers a residual nonspecific repression of
gene expression (Abraham et al., 1999; Paddison et al., 2002a;
P. Paddison and G. Hannon, unpublished data).
One way around these nonspecific dsRNA responses is to
simply create dsRNA triggers of <30 bp in length. In the past
year, two short dsRNA structures have emerged, which evoke
sequence specific gene silencing in somatic cells without activat-
ing antiviral responses. These are the small interfering RNAs
(siRNAs) and the short hairpin RNAs (shRNAs). Both are mod-
eled after biologically active structures in the RNAi pathway:
Dicer cleavage products and small temporal RNAs, respectively.
Tuschl and colleagues and Caplen and colleagues (Elbashir
et al., 2001; Caplen et al., 2001) first demonstrated that small
dsRNAs, resembling siRNAs from other systems, induce
sequence-specific gene silencing when transiently transfected
into mammalian cells.These small interfering RNAs (siRNAs) are
chemically synthesized emulations of Dicer cleavage products,
which are short RNA duplexes ?19 nt in length with 2 nt 3′ over-
hangs on each strand. The siRNAs presumably bypass the
requirement for Dicer and enter the silencing pathway by incorpo-
ration into RISC complexes (Figure 1). The use of siRNAs has
been recently reviewed, in detail, and resources for the design
and use of siRNAs are available from Tom Tuschl’s laboratory
online (http://www.mpibpc.gwdg.de/abteilungen/100/105/sirna.html).
As an alternative strategy, we and others have developed in
vivo expression constructs for small dsRNA triggers in mam-
malian cells, which resemble endogenously expressed hairpin
RNAs (Paddison et al., 2002b; Brummelkamp et al., 2002; Paul
et al., 2002; Sui et al., 2002; Yu et al., 2002; Zeng et al., 2002).
This approach uses small inverted repeats (19–29 nt)
expressed from RNA polymerase III promoter to create short
hairpin RNAs (shRNAs), which can then be processed by Dicer
and shunted into the RNAi pathway (Figure 1). However,
siRNAs can also be produced in vivo by the expression of com-
plementary 19 or 21 nt RNAs from separate RNA polymerase III
transcription units (Lee et al., 2002; Miyagishi and Taira, 2002;
Yu et al., 2002). For some studies, expressed dsRNA triggers
have potential advantages over siRNAs when combined with
well-worn strategies for stable and inducible gene expression in
vitro and in vivo. The details of these strategies are further dis-
cussed below.
One of the major differences between mammalian cell RNAi
and the response observed, for example, in C. elegans is the
apparent lack of amplification of the RNAi effect or of “transitive
RNAi” (Sijen et al., 2001). In C. elegans, “amplification” may
contribute to heritable, systemic gene silencing. According to
one model, amplification of the dsRNA signal is initially mediat-
ed by RNA-dependent RNA polymerases (RdRP). An RNA
degradation product (e.g., an siRNA) may prime RdRPs along
the mRNA template, resulting in the production of dsRNA
homologous to sequences 5′ (i.e., upstream) of the initially tar-
geted sequence (Sijen et al., 2001). When combined with trans-
port, amplification results in a self-propagating silencing effect
throughout the organism. In mammalian cell systems, however,
transient transfection of RNAi triggers, e.g., long dsRNA,
siRNAs, or shRNAs, results in a transient effect, lasting 2–7
days. The longevity of silencing is likely dependent on gene
expression homeostasis (e.g., abundance of mRNA and pro-
tein, stability of the protein, transcriptional feedback loops, etc.),
the half-life of the silencing complex itself, and cell division,
which serves to dilute the effect over time.
Design and expression of dsRNA triggers
Tuschl and colleagues have elaborated several guidelines for
designing siRNA oligos for chemical synthesis (Elbashir et al.,
2002). The selection of the target sequence should avoid
regions of the mRNA which might bind RNA regulatory proteins,
such as 5′ and 3′ UTR and regions close to the start site (<100
nt). Between +100 nt (with the AUG referenced as +1) and the
stop codon, 23 nt sequences conforming to the consensus (5′-
AA[N19]UU-3′, where N is any nucleotide) are selected from the
mRNA sequence. Sequences of >70% or <30% GC content or
which are highly G-rich should be avoided. The siRNA is then
constructed by designing sense and anti-sense (i.e., reverse
complement) N19 sequences, each ending with two 3′ 2-
deoxythymidine residues. Refer to Elbashir et al. (2002) for a
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more detailed protocol. The current, average cost for chemical
synthesis siRNAs is between $270 to $500 per siRNA, depend-
ing on purification and scale of synthesis.
Two less costly strategies for generating siRNAs involve in
vitro transcription reactions using T7 polymerase (Paddison et
al., 2002b, Yu et al., 2002; Donze and Picard, 2002; with com-
mercial kits for this purpose available from New England Biolabs
[http://www.neb.com] and Ambion [http://www.ambion.com]) and
in vitro processing of long dsRNA using the Dicer enzyme (J.
Myers and J. Ferrell, personal communication). T7 generated
siRNAs differ from normal Dicer products in that they contain 5′-
triphosphates. Despite this difference, T7-siRNAs have been
shown to be biologically active. A T7-siRNA design program and
detailed instructions are available at http://www.cshl.org/pub
lic/SCIENCE/hannon.html. In vitro processing of long dsRNA by
purified Dicer enzyme may eventually be the most effective way
to generate siRNAs, since the end products will be a mixture of
dozens of separate siRNAs targeting a single mRNA. However,
siRNA populations will likely require purification to avoid contam-
ination of long dsRNA, and complex siRNA populations may
have a higher probability of targeting other genes than do dis-
crete siRNAs. Regardless of the method used to generate
siRNAs, the major drawback of exogenously produced siRNAs
is the inability to stably or inducibly regulate gene expression.
Toward this end, we and others have developed expression
strategies for dsRNA triggers in embryonal cell types (Billy et al.,
2001; Yang et al., 2001; Paddison et al., 2002a) and in somatic
cells (Brummelkamp et al., 2002; Lee et al., 2002; Miyagishi and
Taira, 2002; Paddison et al., 2002b; Paul et al., 2002; Sui et al.,
2002;Yu et al., 2002; Zeng et al., 2002) (Figure 2).
For cells derived from somatic tissues, a flurry of recent
reports demonstrates that expression of short hairpin RNAs
(shRNAs) or complementary siRNA strands leads to sequence-
specific gene silencing. The basic expression schemes and
expression strategies are presented in Figure 2. Most strategies
use RNA polymerase III promoters (either human or mouse U6-
snRNA or human RNase P [H1] RNA promoters) to drive
expression of short RNAs, since RNA polymerase III can be
exploited to precisely initiate and terminate RNA transcripts
(Goomer and Kunkel, 1992). These promoters should be active
in most if not all embryonal and somatic cell types. One group,
however, successfully triggered silencing by burying a
microRNA structure within an RNA polymerase II-derived tran-
script (Zeng et al., 2002).
There are a few points to note concerning the expression
strategies that have been used thus far. First, U6 derived
shRNAs and siRNAs have sequence constraints, where a G
residue is required for efficient initiation (Goomer and Kunkel,
1992). Second, one report suggests that adding the leader
sequence of 27 nt from the U6 snRNA improves expression
(Paul et al., 2002).Third, there is in vitro data to suggest that the
mouse U6 promoter may be more active in human cells, given
the strong affinity of the SNAP-c complex for the proximal
sequence element (Chong et al., 2001). However, given the
published data and our unpublished results, the minor differ-
ences amongst the reported expression strategies are unlikely
to have a major impact on the efficacy of silencing.
Surprisingly, many of the structural features present in
micro RNAs can be ignored in shRNAs expressed from RNA
polymerase III promoters. When using the human U6 and H1
promoters, we have found that loop structures of 4 or 8 nt work
equally well when comparing the same 19 nt and 29 nt stems
(our unpublished data). Structured stems and loops, modeled
after human let-7-like hairpins (Pasquinelli et al., 2000; Lagos-
Quintana et al., 2001), work considerably less well than perfect-
ly matched stems with simple loops (Paddison et al., 2002b and
our unpublished data). The only differences in efficiency which
arise appear to be dependent upon length of the hairpin stem,
where stems of 29 nt work 10%–40% more efficiently than
stems of 19 nt, at least when targeting reporter genes (our
unpublished data). This modest increase in efficiency must,
however, be balanced against concerns that longer stems could
theoretically increase the possibility of off-target effects. Thus,
the optimal structure for shRNAs will likely emerge only after the
accumulation of copious additional in vivo data with large num-
bers of genes.
Whichever method is used, we suggest selecting 3–6 shRNA
sequences per gene. Empirical data suggests that one or more
RNAi expression construct should give 40%–90% reduction in
gene expression when used transiently. A program for construct-
ing shRNA cloning primers, along with detailed protocols, is avail-
able at http://www.cshl.org/public/SCIENCE/hannon.html.
By default, we use rules similar to those described by Tuschl
and colleagues for choosing shRNA targeting sequences. A tar-
get sequence of 5′-(Nx)C-3′, where N is any nucleotide, x is a
length from 18 to 28 nt, and the targeted sequence contains
between 30%–70% GC, is selected from the target mRNA. We
normally engineer the 5′ stem strand as the anti-sense strand;
however, either strand is effective (our unpublished data;
Brummelkamp et al., 2002; Paddison et al., 2002b; Paul et al.,
2002; Sui et al., 2002; Yu et al., 2002). To aid in cloning and to
increase stability in bacteria, we incorporate G-U base pairs in
the stem of shRNAs, which are permitted in duplexed RNA but
not DNA. However, this strategy has not been used by others
and is likely nonessential.
Delivery strategies
Both siRNAs and vectors containing dsRNA triggers can be
Figure 2. Expression of dsRNA triggers in mammalian cells
This figure shows the various strategies that have been used to express
dsRNA triggers in mammalian cells and some of the structural features of
the dsRNA triggers. Of note is that long hairpins have so far only proven
effective in embryonal cell types, which lack PKR/interferon responses.
Expressed shRNAs and siRNAs, however, evoke sequence-specific silencing
in numerous cell types tested.
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transiently transfected into mammalian cells using commonly
available transfection reagents. Chemically synthesized siRNAs
are reliably effective at concentrations ranging from .05 to .5 nM
in transient transfections, while U6-shRNA vectors are effective
at concentrations normally used for expression of transgenes.
There are a number of well-characterized stable expression
technologies currently being used in mammalian cells, which
should permit permanent expression of shRNAs and siRNAs in
target cells. These include systems based on retroviral integra-
tion (e.g., Hannon et al., 1999; Lois et al., 2002) (Figure 3),
transposon hopping (e.g., Ivics et al., 1997), episomally repli-
cated DNA fragments (e.g., Chittenden et al., 1989; Sedman
and Stenlund, 1995), and homologous recombination (e.g.,
Nagy, 2000).
Among recent reports, stable RNAi has been demonstrated
using random plasmid integration (Brummelkamp et al., 2002;
Paddison et al., 2002b) and episomal plasmid maintenance
(Miyagishi and Taira, 2002). However, based upon our observa-
tions, stable maintenance of RNAi following plasmid integration
may be problematic where the phenotype itself is not positively
selected (e.g., bypass of senescence). Therefore, we have
begun exploring retroviral strategies for stable expression of
shRNAs. We have found that MoMuLV or MSCV vectors harbor-
ing U6-shRNA cassettes can stably evoke RNAi (Figure 3A).
Figure 3 shows bypass of rasV12-induced senescence in early
passage mouse embryo fibroblasts using a mouse p53 shRNA
(Paddison et al., 2002b) expressed from pBabe-Puro
(Morgenstern and Land, 1990). MEFs cotransduced with Wzl-
rasV12 and Babe-Puro alone show a flattened morphology and
growth arrest consistent with cellular senescence (Serrano et
al., 1997; Ferbeyre et al., 2000), while cells cotransduced with
Wzl-rasV12 and Babe-Puro-U6-shRNA-p53 display a trans-
formed morphology with little or no observable growth arrest.
With retrovirus-based strategies, the expression of shRNA dur-
ing virus packaging may result in
reduced virus production. For example,
shRNAs may target viral genomic tran-
scripts in packaging cells or the markers
used for selecting infected cells. Furthermore, targeting essen-
tial genes is likely to have adverse effects on packaging cells.
The movement to inducible RNA pol III promoters should ame-
liorate these problems, and we have recently derived an activa-
tor-dependent, U6-based expression system for shRNAs (P.
Paddison, E. Julien, W. Herr, and G. Hannon, unpublished data).
The above results suggest that retroviral vectors may repre-
sent potent delivery strategies for shRNA expression, although
more work is needed to determine an optimal viral configura-
tion. Of particular interest is the potential to create transgenic
animals through the transduction of preimplantation embryos or
ES cells with suitably modified lentiviral vectors (Lois et al.,
2002; Pfeifer et al., 2002).
RNAi-based screens: applications in cancer cells
In other model systems, the use of genetic screens to explore
functional dependencies has been an enabling feature of count-
less discoveries. For example, analysis of temperature sensitive
mutants in bacteriophage T4 led to the discovery of viral mor-
phogenesis modules (Edgar and Wood, 1966). Similar
approaches in yeast revealed functional hierarchies among
genes regulating cell cycle progression (Hartwell et al., 1974;
Hartwell and Weinert, 1989). The key to such discoveries has
been the ability to create recessive, genetically defined lesions
in molecular pathways.
Since cancer arises from genetic lesions in somatic cells,
the concept of synthetic lethality has been heralded as way to
functionally define vulnerabilities in cancer cells (Hartwell et al.,
1997). Synthetic lethal interactions occur when mutations in two
or more nonallelic genes synergize to kill cells. For example, a
mutation in gene A or gene B may be tolerated when singly pre-
sent in cells, but when combined may result in a loss of viability.
Thus, synthetic lethal interactions reveal situations in which cel-
lular homeostasis is altered by a molecular lesion so that the
Figure 3. Stable expression of an shRNA using a
retroviral system
This figure depicts one strategy for expressing
shRNAs from retroviruses. A U6-p53-shRNA was
inserted into the 3′ LTR of a MoMuLV pBabe-Puro
retroviral construct. A: The predicted structure
and orientation of the retrovirus as integrated
into the genome of the infected cell. B: The pre-
dicted structure of a murine p53 shRNA. C: An
assay for bypass of rasV12-induced senescence
in early passage mouse embryo fibroblasts (P2).
Cells were first transduced with Babe-Puro alone
or Babe-Puro-LTR-U6-p53-shRNA and selected in
puromycin for 3 days, after which cells were
infected with Wzl-Hygro-rasV12 and treated
with hygromycin. Only cells initially receiving
Babe-Puro-LTR-p53-shRNA were morphological-
ly transformed by rasV12 and continued to
divide (see text). A time point 5 days after trans-
duction with rasV12 is shown. Potential compli-
cations with this strategy would arise if shRNAs
target viral and drug resistance transcripts in
packaging or target cells, or if shRNAs target
essential genes in the packaging cells.
Therefore, we are currently designing inducible
U6 constructs for expression from self-inactivat-
ing retroviruses.
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action of another gene or pathway is required to compensate.
The fact that cancer cells arise from genetic alterations makes
synthetic lethality ideally suited for identifying cellular targets
required by cancer cells for viability.
Our group is currently in the process of undertaking large-
scale RNAi-based screens for lethal targets in cancer cell lines.
The biggest question in regard to designing mammalian cell
screens is whether to use forward or reverse genetic approach-
es. Randomized, forward genetic screens have been used with
some degree of success in mammalian systems for gain of
function genetic lesions. Such screens generally consist of
expressing, in mass, cDNAs or genomic fragments in receipt
cell populations and screening for a positively selectable pheno-
type (e.g., Deiss and Kimchi, 1991; Wong et al., 1994; Maestro
et al., 1999; reviewed in Gudkov and Roninson, 1997). Perhaps
the best example of this type of approach came early on with
the cloning of the ras oncogene from genomic libraries in rodent
cells (Goldfarb et al., 1982; Shih and Weinberg, 1982). While
such approaches are compatible with RNAi-induced pheno-
types (e.g., bypass of senescence), a well-to-well, reverse
genetic approach has two major advantages. First, neutral or
negatively selected phenotypes (e.g., apoptosis, growth arrest)
can be scored in each well for single and multiple gene targeting
events. Second, RNAi expression constructs can be assembled
into restricted functional sets a priori based on known or
inferred function of gene targets (e.g., DNA replication, DNA
damage repair, etc.). Comparing phenotypic readouts among
different restricted sets may give rise to “epistasis signatures,”
or maps of functional dependencies underlying a particular phe-
notype in a particular genetic background (e.g., transformed
versus nontransformed cells). Such signatures would be com-
parable to transcript array patterns, except that epistasis signa-
tures would be functionally defined and thus, although less pre-
cise, potentially more suggestive of cause and consequence.
Perspectives
Through the use of reverse genetic
approaches, RNAi has developed into a
powerful tool for probing gene function in
C. elegans and other invertebrate sys-
tems. In worms, RNAi is currently being
used to systematically target ?19,000
predicted genes (J. Ahringer, personal
communication). Similar approaches are
underway in plants (D. Baulcombe and P.
Waterhouse, personal communication).
With the added capacity of RNAi, somat-
ic mammalian cells will hopefully gain
admittance into the pantheon of model
genetic systems. In practical terms, the
use of RNAi in cultured cells may deliver
new insights into a host of disease-related processes, including
concrete information on potential drug targets.
RNAi also holds promise for in vivo genetic applications in
mammals. Perhaps the most immediate question is whether
expressed RNAi triggers can be combined with transgenic
approaches for stably knocking down gene expression in
rodents (Figure 4). Studies of ex vivo modified cells can also
benefit from RNAi, where primary or transformed cells are sta-
bly engineered with shRNAs and then implanted into mice.
Inducible RNAi triggers may ultimately prove to be key compo-
nents of both in vivo and ex vivo approaches in rodent systems
(Figure 4).
In humans, there are many scenarios in which RNAi could
be enlisted to combat disease. These include targeting viral
pathogens, targeting disease- or symptom-causing genes (or
alleles), modifying primary cells ex vivo to remove undesirable
gene products, expressing shRNAs from replication competent
viruses to selectively kill cancer cells, and so on (Figure 4). With
regard to target specificity, dsRNA triggers of gene silencing are
well-suited as therapeutic molecules, since gene products are
targeted based on mRNA sequence rather than protein activity,
and are thus not limited by the ability of medicinal chemistry to
target a protein class or interaction. However, at present, effec-
tive delivery strategies present a significant barrier to therapeu-
tic applications of RNAi.
RNAi shows tremendous promise as a new technology for
manipulating gene expression for both experimental and thera-
peutic purposes. However, we are still in the very early stages of
understanding both the mechanistic basis and biological roles
of these gene-silencing pathways. Thus, we will undoubtedly
see both spectacular successes and notable failures of RNAi
before we fully understand the power and limitations of this new
tool.
Figure 4. Potential applications of RNAi in mam-
malians
This figure shows some potential applications of
dsRNA triggers of gene silencing in mammals.
We envision that both siRNA and expressed
shRNAs and siRNAs will have broad utility for
genetically manipulating cells both in vivo and
in vitro. Applications may range from finding
new drug targets in culture cells, to modeling
tumor behavior in mouse models, to applying
RNAi as a therapeutic tool in the clinic.
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